* indicates required field
| CoC | SEER | NPCR | CCCR | |
|---|---|---|---|---|
| 1 | Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). | Behavior code of 2 or 3 in ICD-O-3.2 plus the ICD-O-3.2 updates posted on the NAACCR website or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). | Behavior code 2 or 3 in ICD-O-3.2; behavior code 3 in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) (2010+); behavior code 2 or 3 in WHO Classification of Tumours 5th Ed. (2022+) (Refer to instructions provided by NPCR for detailed information.) | Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). |
| 2 | For cases diagnosed prior to 1/1/2023, pilocytic astrocytoma/juvenile pilocytic astrocytoma are reportable in North American as malignant 9421/3 for all CNS sites with the exception of the optic nerve. When the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma, the behavior is non-malignant and coded 9421/1. Beginning with cases diagnosed 1/1/2023 forward, pilocytic astrocytoma/juvenile pilocytic astrocytoma are to be reported as 9421/1 for all CNS sites.
| For cases diagnosed prior to 1/1/2023, pilocytic astrocytoma/juvenile pilocytic astrocytoma are reportable in North American as malignant 9421/3 for all CNS sites with the exception of the optic nerve. When the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma, the behavior is non-malignant and coded 9421/1. Beginning with cases diagnosed 1/1/2023 forward, pilocytic astrocytoma/juvenile pilocytic astrocytoma are to be reported as 9421/1 for all CNS sites.
| For cases diagnosed prior to 1/1/2023, pilocytic astrocytoma/juvenile pilocytic astrocytoma are reportable in North American as malignant 9421/3 for all CNS sites with the exception of the optic nerve. When the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma, the behavior is non-malignant and coded 9421/1. Beginning with cases diagnosed 1/1/2023 forward, pilocytic astrocytoma/juvenile pilocytic astrocytoma are to be reported as 9421/1 for all CNS sites.
| Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors (ICD-O-3 topography codes C70-C72) (1/1/1992). |
| 3 | As of 01/01/2021, early or evolving melanoma in situ or invasive, or any other early or evolving melanoma, is reportable. | Early or evolving melanoma in situ, or any other early or evolving melanoma (2021+). | Early or evolving melanoma in situ, or any other early or evolving melanoma (2021+). | |
| 4 | Carcinoid, NOS of the appendix C181 (as of 1/1/2015). | Carcinoid, NOS of the appendix C181 (as of 1/1/2015). | Carcinoid, NOS of the appendix C181, behavior changed to 3 effective 2015 (2015+). | Carcinoid, NOS of the appendix C181 (as of 1/1/2012). |
| 5 | Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia is reportable. For neoplasms of the pancreas, the term MCN with high grade dysplasia replaces the term mucinous cystadenocarcinoma, non-invasive. | |||
| 6 | Non-malignant (behavior codes 0 and 1) primary endocrine glands and related structures (ICD-O-3 Topography codes C75.1-C75.3) (1/1/2007). | |||
| 7 | Non-malignant Borderline (behavior code 1) (all topographies in ICD-O-3) (1/1/1992 to 12/31/2020).
| |||
| 8 | Non-malignant GIST tumors with multiple foci, mets, or positive LNs must be assigned behavior 3 (2021+) | All GIST are reportable as of 01/01/2021 except for those specifically stated to be benign. The behavior code for GIST is /3 in ICD-O-3.2. | GIST tumors, all histologies changed to behavior 3 in ICD-O-3.2 (2021+). | GIST tumors, all histologies changed to behavior 3 in ICD-O-3.2 (2021 +). |
| 9 | Non-malignant thymomas with multiple foci, mets, or positive LNs must be assigned behavior 3 (2021+) | Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0). | Thymomas, most behaviors changed to 3 in ICD-O-3.2. (2021+) See exceptions listed below. | Thymomas, most behaviors changed to 3 in ICD-O-3.2. (2021+) See exceptions listed below. |
| 10 | SIN III is collected. | Intraepithelial neoplasia, high grade, grade II, grade III | ||
| 11 | Non-invasive follicular thyroid neoplasm with papillary-like nuclear features, NIFTP, Non-invasive encapsulated follicular variant of papillary thyroid carcinoma EFVPTC, (8343/2 with C73.9) (1/1/2017-12/31/2020). | |||
| 12 | Lobular carcinoma in situ (LCIS) of breast
7. Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (as of 1/1/2016). | Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (/2016+). | Lobular carcinoma in situ (LCIS) of breast.
Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (/2016+). | |
| 13 | Pancreatic intraepithelial neoplasia (PanIN III) (as of 1/1/2016). | Pancreatic intraepithelial neoplasia (PanIN III) (2016+). | Pancreatic intraepithelial neoplasia (PanIN III) (2016+). | |
| 14 | Penile intraepithelial neoplasia III (PeIN III) (as of 1/1/2016). | Penile intraepithelial neoplasia III (PeIN III) (2016+). | Penile intraepithelial neoplasia III (PeIN III) (2016+). | |
| 15 | Clear cell papillary renal cell carcinoma 8323/3 is reportable. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs, 4th Edition, has reclassified this histology as a /1 because it is low nuclear grade and is now thought to be a neoplasia. This change has not yet been implemented and it remains reportable. | Clear cell papillary renal cell carcinoma 8323/3 is reportable. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs, 4th Edition, has reclassified this histology as a /1 because it is low nuclear grade and is now thought to be a neoplasia. This change has not yet been implemented and it remains reportable. | ||
| 16 | 8480/2 Low-grade appendiceal mucinous neoplasm (LAMN) (2022+)
8480/2 High grade appendiceal mucinous neoplasm (HAMN) (2022+)
8480/3 Low-grade appendiceal mucinous neoplasm (LAMN) (2022+)
8480/2 High grade appendiceal mucinous neoplasm (HAMN) (2022+)
8480/3 Appendiceal mucinous neoplasm with extraappendiceal spread (2022+)
Low grade appendiceal mucinous neoplasms (LAMN) (8480) (2023+) | Low-grade appendiceal mucinous neoplasm (LAMN) now has a behavior of /2 and /3 making it reportable. The ICD-O Committee and authors of the WHO Classification of Tumors of the Digestive System, 5th Edition agreed to issue corrigenda.
Corrigenda – Appendiceal mucinous neoplasm 8480/2 High-grade appendiceal mucinous neoplasm 8480/3 Appendiceal mucinous neoplasm with extra-appendiceal spread. | Low-grade appendiceal mucinous neoplasm (LAMN) behavior changed to 2 effective 2022 (2022+).
High-grade appendiceal mucinous neoplasm (HAMN) behavior changed to 2 effective 2022 (2022+). | Low-grade appendiceal mucinous neoplasm (LAMN) behavior changed to 2 effective 2022 (1/1/2022).
High-grade appendiceal mucinous neoplasm (HAMN) behavior changed to 2 effective 2022 (1/1/2022).
Appendiceal mucinous neoplasm with extra-appendiceal spread, behaviour changed to 3 effective 2022 (1/1/2022). |
| 17 | High-grade astrocytoma with piloid features (HGAP) (9421/3) | |||
| 18 | Lymphangioleiomyomatosis (9174/3) | |||
| 19 | Mesothelioma in situ (9050/2) | |||
| 20 | Diffuse leptomeningeal glioneuronal tumor (9509/3) | |||
| 21 | Report diffuse astrocytoma, MYB- or MYBL1-altered and diffuse low-grade glioma, MAPK pathway-altered (9421/1) | |||
| 22 | Report multinodular and vacuolating neuronal tumor (9509/0) | |||
| 23 | Report juvenile xanthogranuloma (9749/1) | |||
| 24 | Placental site trophoblastic tumor of testis is reportable as 9104/3. |
| CoC | SEER | NPCR | CCCR | |
|---|---|---|---|---|
| 1 | Skin cancers (C44._) with histology 8000-8110 (after 1/1/2003); prior to that date, AJCC stage groups 2-4 in this group were reportable. | Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110. | Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110. | Skin cancers (C44._) with histologies 8050-8084, 8090-8110 (1/1/1992). |
| 2 | Skin cancers (C44._) with histologies 8000-8005, 8010-8046 (1/1/2007). | |||
| 3 | CIS of the cervix and CIN III (after 1/1/96). | CIS of the cervix and CIN III or SIN III of cervix (after 1/1/96). | CIS of the cervix and CIN III or SIN III. | CIS of the cervix and CIN III or SIN III. (1/1/2007). |
| 4 | There are two new histology codes for HPV-related adenocarcinoma in situ of the cervix. These are not reportable. | |||
| 5 | PIN III (after 1/1/96). | PIN III (after 1/1/2001). | PIN III (2001+). | PIN III of the prostate (1/1/2007). |
| 6 | VIN III (after 1/1/96). | |||
| 7 | VAIN III (after 1/1/96). | |||
| 8 | AIN (after 1/1/96). | |||
| 9 | Microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0). | |||
| 10 | High grade dysplasia of the colon is not reportable even though it has been designated in situ (/2) in the latest WHO classification. | Colorectal tumors with the following morphologic description: Serrated dysplasia, high grade; Adenomatous polyp, high mgrade dysplasia; Tubular adenoma, high grade; Villous adenoa, high grade; Tubulovillos adenoma, high grade. | In situ (behaviour code of 2 in ICD-O-3) of the colon and rectum with histology 8148 (1/1/2019). | |
| 11 | Colon atypical hyperplasia | |||
| 12 | 8210/2 Adenomatous polyp, high grade dysplasia (C160 – C166, C168-C169, C170-C173, C178-C179) | |||
| 13 | 8211/2 Tubular adenoma, high grade | |||
| 14 | 8261/2 Villous adenoma, high grade | |||
| 15 | 8263/2 Tubulovillous adenoma, high grade | |||
| 16 | 8483/2 Adenocarcinoma in situ, HPV-associated (C530-C531, C538-C539) | |||
| 17 | 8484/2 Adenocarcinoma in situ, HPV-independent, NOS (C530-C531, C538-C539) | |||
| 18 | 8509/1 Uterine tumor resembling ovarian sex cord tumor | |||
| 19 | 9200/1 Osteoblastoma | |||
| 20 | 9261/1 Osteofibrous dysplasia-like adamantinoma. | |||
| 21 | 8520/2 Lobular carcinoma in situ of the breast (C50.0-C50.9) (after 01/01/2018) |